| 
                    
                        FMODexpression in whole blood aids in distinguishing between chronic lymphocytic leukemia and other leukemic lymphoproliferative disorders. A pilot study
                    Por:
                    Sorigue, M, Junca, J, Ferra, C, Marce, S, Ruiz-Xiville, N, Pinyol, L, Cabezon, M, Espasa, A, Dominguez, D, Lopez-Viaplana, L, Ruiz, R, Buch, J, Plensa, E, Mostacedo, SZ, Aranda, J, Vergara, S, Raya, M, Granada, I, Tapia, G, Navarro, JT, Bea, S and Zamora, LPublicada:
                    1 sep 2020
                    Ahead of Print:
                    1 jun 2020
 
 
                        Resumen:
                        Background Within the hematopoietic compartment, fibromodulin (FMOD) is almost exclusively expressed in chronic lymphocytic leukemia (CLL) lymphocytes. We set out to determine whether FMOD could be of help in diagnosing borderline lymphoproliferative disorders (LPD). Methods We established 3 flow cytometry-defined groups (CLL [n= 65], borderline LPD [n= 28], broadly defined as those with CLLflow score between 35 and -20 or discordant CD43 and CLLflow, and non-CLL LPD [n= 40]). FMOD expression levels were determined by standard RT-PCR in whole-blood samples. Patients were included regardless of lymphocyte count but with tumor burden >= 40%. Results FMOD expression levels distinguished between CLL (median 98.5, interquartile range [IQR] 37.8-195.1) and non-CLL LPD (median 0.012, IQR 0.003-0.033) with a sensitivity and specificity of 1. Most borderline LPDs were CD5/CD23/CD200-positive with no loss of B-cell antigens and negative or partial expression of CD43. 16/22 patients with available cytogenetic analysis showed trisomy 12. In 25/28 (89%) of these patients, FMOD expression levels fell between CLL and non-CLL (median 3.58, IQR 1.06-6.21). Discussion This study could suggest that borderline LPDs may constitute a distinct group laying in the biological spectrum of chronic leukemic LPDs. Future studies will have to confirm these results with other biological data. Quantification of FMOD can potentially be of help in the diagnosis of phenotypically complex LPDs.
 
 Filiaciones:
 :
                             Univ Autonoma Barcelona, ICO Hosp Germans Trias & Pujol, Inst Recerca Josep Carreras, Hematol Lab, Badalona, Spain
 
 :
                             Univ Autonoma Barcelona, ICO Hosp Germans Trias & Pujol, Inst Recerca Josep Carreras, Hematol Lab, Badalona, Spain
 
 :
                             Univ Autonoma Barcelona, ICO Hosp Germans Trias & Pujol, Inst Recerca Josep Carreras, Dept Clin Haematol, Badalona, Spain
 
 :
                             Univ Autonoma Barcelona, ICO Hosp Germans Trias & Pujol, Inst Recerca Josep Carreras, Hematol Lab, Badalona, Spain
 
 :
                             Univ Autonoma Barcelona, ICO Hosp Germans Trias & Pujol, Inst Recerca Josep Carreras, Hematol Lab, Badalona, Spain
 Pinyol, L
 :
                             Univ Autonoma Barcelona, ICO Hosp Germans Trias & Pujol, Inst Recerca Josep Carreras, Hematol Lab, Badalona, Spain
 
 :
                             Univ Autonoma Barcelona, ICO Hosp Germans Trias & Pujol, Inst Recerca Josep Carreras, Hematol Lab, Badalona, Spain
 Espasa, A
 :
                             Univ Autonoma Barcelona, ICO Hosp Germans Trias & Pujol, Inst Recerca Josep Carreras, Hematol Lab, Badalona, Spain
 
 :
                             Univ Autonoma Barcelona, ICO Hosp Germans Trias & Pujol, Inst Recerca Josep Carreras, Hematol Lab, Badalona, Spain
 Lopez-Viaplana, L
 :
                             Hosp Mataro, Dept Hematol, Barcelona, Spain
 Ruiz, R
 :
                             Inst Josep Carreres Leucemia, Badalona, Spain
 Buch, J
 :
                             Hosp Calella, Dept Hematol, Calella, Spain
 
 ICO Girona, Girona, Spain
 Plensa, E
 :
                             Hosp Mataro, Dept Hematol, Barcelona, Spain
 Mostacedo, SZ
 :
                             Hosp Calella, Dept Hematol, Calella, Spain
 
 ICO Girona, Girona, Spain
 Aranda, J
 :
                             Inst Josep Carreres Leucemia, Badalona, Spain
 Vergara, S
 :
                             Univ Autonoma Barcelona, ICO Hosp Germans Trias & Pujol, Inst Recerca Josep Carreras, Hematol Lab, Badalona, Spain
 Raya, M
 :
                             Univ Autonoma Barcelona, ICO Hosp Germans Trias & Pujol, Inst Recerca Josep Carreras, Hematol Lab, Badalona, Spain
 
 :
                             Univ Autonoma Barcelona, ICO Hosp Germans Trias & Pujol, Inst Recerca Josep Carreras, Hematol Lab, Badalona, Spain
 
 :
                             Hosp Badalona Germans Trias & Pujol, Dept Pathol, Badalona, Spain
 
 :
                             Univ Autonoma Barcelona, ICO Hosp Germans Trias & Pujol, Inst Recerca Josep Carreras, Hematol Lab, Badalona, Spain
 Bea, S
 :
                             Inst Invest Biomed August Pi & Sunyer IDIBAP, Barcelona, Spain
 
 Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
 
 Univ Barcelona, Barcelona, Spain
 
 :
                             Univ Autonoma Barcelona, ICO Hosp Germans Trias & Pujol, Inst Recerca Josep Carreras, Hematol Lab, Badalona, Spain
 
 
                        
                     |